Trial Information

Summary: A Phase I Study of the Combination of Radiation Therapy (RT), Arsenic Trioxide (ATO) and Temozolomide (TMZ) in Patients with Newly-Diagnosed Glioblastoma Multiforme (GBM)

You have been asked to participate in this research study because you have been recently diagnosed with a malignant brain tumor called a glioblastoma (GBM). The purpose of this study is to find the highest dose of arsenic trioxide (ATO) that can be given in combination with temozolomide (TMZ) and radiation therapy (RT) without causing unmanageable side effects and to learn what side effects that this therapy may cause. Your treatment in this study is expected to last about 6 weeks. Afterwards, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 3:02:34 PM